Abstract
The use of [18F]- and [68Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
Original language | English |
---|---|
Pages (from-to) | 485-487 |
Number of pages | 3 |
Journal | European Urology |
Volume | 73 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2018 |
Externally published | Yes |